A large Danish study involving over 132,000 people has found that starting statin treatment within a year of being diagnosed with type 2 diabetes may be linked to a 15% lower relative risk of developing dementia over the next 10 years. Those who began taking statins between one and five years after their diabetes diagnosis had a 10% lower risk. The findings were presented at the ESC Congress 2026 and published in The Lancet Regional Health - Europe. The research used a statistical method called a clone-censor-weight design to compare dementia rates based on when participants started statin therapy. The study followed individuals through the end of 2021, using their medical records to track dementia diagnoses. This approach allowed researchers to analyze how the timing of statin treatment affected the risk of dementia. Statin drugs are commonly prescribed to lower cholesterol levels and reduce the risk of heart disease. This study suggests they might also offer some protection against dementia, possibly due to their effect on cholesterol, which is often high in people with type 2 diabetes. These individuals already have a higher risk of dementia, making cholesterol management even more important. While the study highlights a potential benefit of early statin use, it is observational, meaning it cannot prove that statins directly prevent dementia. Researchers caution that more studies are needed to confirm these findings. They also stress the importance of ongoing discussions between patients and healthcare providers to make informed decisions about treatment.